GlassScriptPhysician profile
Melissa K Borges
NPI 1841857505
$3,764.45
in general payments reported to CMS, 2019-2025
29 companies · $1,841 in 2025
The $1,841 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $15.83 · 2023: $449 · 2024: $988 · 2025: $1,841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,166 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,165.85 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $511.54 | 2021-2025 | |
| Sk Life Science, INC. | $490.68 | 2023-2025 | |
| Pfizer INC. | $485.96 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $409.92 | 2023-2025 | Austedo Xr, Austedo Xr |
| Biogen, INC. | $274.88 | 2021-2025 | Skyclarys, Vumerity, Tysabri |
| Sumitomo Pharma America, INC. | $265.77 | 2023-2024 | Aptiom |
| Lilly USA, LLC | $149.47 | 2024-2025 | Emgality, Zepbound, Amyvid |
| Lundbeck LLC | $145.19 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $113.43 | 2021-2025 | |
| Cycle Pharmaceuticals INC | $102.46 | 2025 | Tascenso Odt, Bafiertam |
| Neurelis, INC. | $97.27 | 2021-2025 | Valtoco |
| Noctrix Health, INC. | $85.13 | 2024 | Nidra |
| Biohaven Pharmaceuticals, INC. | $75.12 | 2021 | |
| Emd Serono, INC. | $68.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $62.50 | 2021-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $60.56 | 2025 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $53.32 | 2024-2025 | Rexulti |
| Insightec,INC | $51.43 | 2024-2025 | Exablate |
| Celgene Corporation | $46.35 | 2021-2023 | Zeposia |
| Argenx US, INC. | $34.22 | 2024 | Vyvgart |
| Azurity Pharmaceuticals, INC. | $26.25 | 2025 | Horizant |
| Scilex Pharmaceuticals INC. | $24.93 | 2024 | |
| Sanofi-Aventis U.S. LLC | $20.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.17 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.75 | 2021 | |
| Merck Sharp & Dohme LLC | $19.52 | 2021 | |
| Aucta Pharmaceuticals, INC. | $18.04 | 2025 | Motpoly Xr |
| Sunovion Pharmaceuticals INC. | $15.83 | 2022 | |
| Livanova USA, INC. | $15.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Borges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.